TradeOrgs
  • 🇮🇳 India
  • 🇺🇸 US
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← US stocks

🇺🇸ACET

Adicet Bio, Inc. - Common Stock

NASDAQ
$2.78
▼ $1.79 (-39.2%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 17 Nov 2026
H $9.97L $2.60-65.0%
$9.97$8.5$7.02$5.55$4.07$2.6$2.78
RSI (14)
Intraday · 15-minBuy+20RSI 54UptrendMACD Bearishfor day-trading context — not advice

Technical signal

Sell-15
RSI (14)19
oversold 30overbought 70
Trend
Downtrend
MACD
Bullish
Bollinger
Within bands
vs 20-day
below
vs 50-day
below
vs 200-day
below
Support
$2.60
Resistance
$4.74
  • Price is below its 50-day average (medium-term weakness).
  • RSI is 19 — oversold, a level some traders read as a potential entry zone.

Signal backtest · 2026-02-17 → 2026-11-17

Strategy return
-43.0%
Buy & hold
-60.5%
Trades
7
Win rate
0%

$100,000.00 invested would be worth $56,987.10 (-43.0%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About Adicet Bio, Inc.· Biotechnology

source: yahoo

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Employees
102
Headquarters
Boston, United States
www.adicetbio.com ↗

Fundamentals

No fundamental data is currently available for this listing from our data providers.

Recent news

News sentiment:▲ Positive1↑ · 0↓ · 7–
  • Adicet Bio (ACET) Stock Fair Value Moves Lower After Prula Cel Lupus Data— Neutral
    Simply Wall St. · 11 Nov 2026
  • Adicet Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates— Neutral
    Business Wire · 05 Nov 2026
  • Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)— Neutral
    Business Wire · 30 Oct 2026
  • Adicet Bio to Participate in Upcoming Investor Conferences

Educational technical indicators — not investment advice. TradeOrgs does not place trades.

— Neutral
Business Wire · 22 Oct 2026
  • Adicet Bio’s Prula-Cel Delivers 54% Lupus Remission Rate at 12 Months— Neutral
    MarketBeat · 03 Oct 2026
  • Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)— Neutral
    Business Wire · 30 Sept 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.